Literature DB >> 19757196

The effect of LMWH (Nadroparin) on tumor progression.

Zsuzsanna Nagy1, Vera Turcsik, György Blaskó.   

Abstract

Recent clinical studies on patients with malignancies, who were treated with UHF and LMWHs raised the possibility, that these agents may possess an inhibitory effect on tumor progression. Further studies supported that this effect is independent from the anticoagulant and antithrombotic action. In this retrospective study oncological patients with an increased risk for thromboembolism were choosen, who received prophylactic treatment with an LMWH (nadroparin) at least for 6 months. Comparing with the control group, in some subgroups (T3 and T4, as well as M1) the LMWH-treated patients showed a significantly increased survival.

Entities:  

Mesh：

Substances：

Year:  2009        PMID： 19757196     DOI： 10.1007/s12253-009-9204-7

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN： 1219-4956            Impact factor:   3.201


  13 in total

Review 1.  Low-molecular-weight heparin and survival in patients with malignant disease.

Authors:  Ajay K Kakkar
Journal:  Cancer Control       Date:  2005-09       Impact factor: 3.302

Review 2.  The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of randomized trials.

Authors:  A Lazo-Langner; G D Goss; J N Spaans; M A Rodger
Journal:  J Thromb Haemost       Date:  2007-04       Impact factor: 5.824

Review 3.  The heparins and cancer: review of clinical trials and biological properties.

Authors:  Roberto Castelli; Fernando Porro; Paolo Tarsia
Journal:  Vasc Med       Date:  2004-05       Impact factor: 3.239

4.  The effect of low molecular weight heparin on survival in patients with advanced malignancy.

Authors:  Clara P W Klerk; Susanne M Smorenburg; Hans-Martin Otten; Anthonie W A Lensing; Martin H Prins; Franco Piovella; Paolo Prandoni; Monique M E M Bos; Dick J Richel; Geertjan van Tienhoven; Harry R Büller
Journal:  J Clin Oncol       Date:  2005-02-07       Impact factor: 44.544

Review 5.  Non-anticoagulant heparins and inhibition of cancer.

Authors:  Benito Casu; Israel Vlodavsky; Ralph D Sanderson
Journal:  Pathophysiol Haemost Thromb       Date:  2009-01-27

6.  Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

Authors:  Ajay K Kakkar; Mark N Levine; Zbigniew Kadziola; Nicholas R Lemoine; Vanessa Low; Heman K Patel; Gordon Rustin; Michael Thomas; Mary Quigley; Robin C N Williamson
Journal:  J Clin Oncol       Date:  2004-05-15       Impact factor: 44.544

Review 7.  Heparanase, heparin and the coagulation system in cancer progression.

Authors:  Israel Vlodavsky; Neta Ilan; Yona Nadir; Benjamin Brenner; Ben-Zion Katz; Annamaria Naggi; Giangiacomo Torri; Benito Casu; Ram Sasisekharan
Journal:  Thromb Res       Date:  2007       Impact factor: 3.944

8.  Effect of low-molecular-weight heparin on survival in patients with advanced pancreatic adenocarcinoma.

Authors:  Stefan von Delius; Muhammed Ayvaz; Stefan Wagenpfeil; Florian Eckel; Roland M Schmid; Christian Lersch
Journal:  Thromb Haemost       Date:  2007-08       Impact factor: 5.249

Review 9.  Heparin, heparan sulfate and heparanase in cancer: remedy for metastasis?

Authors:  Jin-Ping Li
Journal:  Anticancer Agents Med Chem       Date:  2008-01       Impact factor: 2.505

Review 10.  Parenteral anticoagulation may prolong the survival of patients with limited small cell lung cancer: a Cochrane systematic review.

Authors:  Elie A Akl; Frederiek F van Doormaal; Maddalena Barba; Ganesh Kamath; Seo Young Kim; Saskia Kuipers; Saskia Middeldorp; Victor Yosuico; Heather O Dickinson; Holger J Schünemann
Journal:  J Exp Clin Cancer Res       Date:  2008-05-15
View more
  11 in total

1.  D-dimer as a potential prognostic marker.

Authors:  Zsuzsanna Nagy; Orsolya Horváth; Julia Kádas; Dorottya Valtinyi; Larisza László; Bence Kopper; György Blaskó
Journal:  Pathol Oncol Res       Date:  2012-07       Impact factor: 3.201

2.  The effect of low-molecular-weight heparin in cancer patients: the mirror image of survival?

Authors:  Sandro Barni; Erminio Bonizzoni; Melina Verso; Gualberto Gussoni; Fausto Petrelli; Tania Perrone; Giancarlo Agnelli
Journal:  Blood       Date:  2014-07-03       Impact factor: 22.113

Review 3.  Targeting heparin and heparan sulfate protein interactions.

Authors:  Ryan J Weiss; Jeffrey D Esko; Yitzhak Tor
Journal:  Org Biomol Chem       Date:  2017-06-27       Impact factor: 3.876

4.  Significantly inhibitory effects of low molecular weight heparin (Fraxiparine) on the motility of lung cancer cells and its related mechanism.

Authors:  Guo-xing Zhong; Yi Gong; Chuan-jiang Yu; Shi-fei Wu; Qing-ping Ma; Yu Wang; Jiang Ren; Xue-chao Zhang; Wei-han Yang; Wen Zhu
Journal:  Tumour Biol       Date:  2015-01-27

5.  Effect of Fraxiparine, a type of low molecular weight heparin, on the invasion and metastasis of lung adenocarcinoma A549 cells.

Authors:  Chuan-Jiang Yu; Su-Juan Ye; Zhi-Hua Feng; Wen-Jing Ou; Xi-Kun Zhou; Ling-Dong Li; Yong-Qiu Mao; Wen Zhu; Yu-Quan Wei
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

6.  Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response.

Authors:  Elisabeth M Battinelli; Beth A Markens; Rajesh A Kulenthirarajan; Kellie R Machlus; Robert Flaumenhaft; Joseph E Italiano
Journal:  Blood       Date:  2013-09-24       Impact factor: 22.113

7.  Comparative outcomes of thrombocytopenic acute leukemic patients with venous thromboembolism at a Comprehensive Cancer Center.

Authors:  Maliha Khan; Travis M Cox; Mohammed Nassif; Mohanad A Alzubaidi; Naveen Garg; Wei Qiao; Fleur M Aung; Thein Hlaing Oo; Cristhiam M Rojas-Hernandez
Journal:  J Thromb Thrombolysis       Date:  2018-04       Impact factor: 2.300

Review 8.  Antithrombotic therapy for ambulatory patients with multiple myeloma receiving immunomodulatory agents.

Authors:  Lara A Kahale; Charbel F Matar; Ibrahim Tsolakian; Maram B Hakoum; Victor Ed Yosuico; Irene Terrenato; Francesca Sperati; Maddalena Barba; Lisa K Hicks; Holger Schünemann; Elie A Akl
Journal:  Cochrane Database Syst Rev       Date:  2021-09-28

9.  Combination therapy with low molecular weight heparin and Adriamycin results in decreased breast cancer cell metastasis in C3H mice.

Authors:  Weiwei Yin; Jing Zhang; Yumin Jiang; Shen Juan
Journal:  Exp Ther Med       Date:  2014-08-18       Impact factor: 2.447

10.  Heparin inhibits Hepatocyte Growth Factor induced motility and invasion of hepatocellular carcinoma cells through early growth response protein 1.

Authors:  Evin Ozen; Aysim Gozukizil; Esra Erdal; Aykut Uren; Donald P Bottaro; Nese Atabey
Journal:  PLoS One       Date:  2012-08-13       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.